Anti Amyloid Leqembi denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for anti amyloid leqembi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Leqembi for Medical Necessity — and How to Build a Winning Appeal

A medical-necessity denial for Leqembi (lecanemab) means Aetna reviewed your prior-authorization request and concluded that your submitted documentation did not demonstrate that you meet the clinical criteria required for coverage. This is rarely a final answer — it most often means the submission was incomplete, the clinical narrative was not specific enough, or the documentation did not directly address each criterion in Aetna's coverage policy. A well-structured appeal that maps every coverage criterion to a specific chart fact has a strong track record of success.

## Why This Denial Happens

Aetna's medical-necessity criteria for anti-amyloid therapies typically require confirmation of the diagnosis at a specific stage of disease, confirmation of amyloid pathology through an accepted method, and documentation that the patient's clinical profile falls within the FDA-approved indication. When any single element is absent, ambiguous, or documented in a way that does not align with the terminology in the coverage policy, the system may generate a denial. The denial is a documentation gap, not necessarily a clinical one.

## Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): You have the right to a full-and-fair internal appeal reviewed by a qualified clinical reviewer not involved in the original decision. Submit within the timeframe on the denial notice.
• Expedited appeal: If your neurologist certifies that waiting for a standard review poses a serious health risk, Aetna must respond within 72 hours.
• External review: If the internal appeal is denied, you may request independent external review within approximately four months of the final denial. The IRO applies medical evidence standards and is not bound by Aetna's internal coverage policy language. IRO decisions are binding.

## Documentation to Gather

1. Specialist diagnosis note — A neurologist or geriatric psychiatrist's note explicitly confirming early symptomatic Alzheimer's disease with clinical staging details. 2. Amyloid confirmation — PET imaging report or CSF biomarker analysis confirming amyloid pathology, with the date of testing and the interpreting physician's conclusion. 3. Cognitive and functional assessment — Standardized assessment results from the chart, dated, showing the patient's current cognitive and functional status. 4. Prior treatment history — A documented list of previously tried Alzheimer's-related treatments, with dates, prescribed regimens, and outcomes — relevant if Aetna's policy requires prior therapy. 5. Prescriber medical-necessity letter — A detailed letter from the neurologist that walks through each of Aetna's coverage criteria and cites the specific chart evidence that satisfies each one. This is the single most important document in a medical-necessity appeal. 6. Aetna's coverage policy — Obtain the current version and use it as your appeal checklist.

## Criteria-Mapping Structure for Your Appeal

For every criterion in Aetna's coverage policy, create a row in your appeal:

| Aetna Coverage Criterion | Satisfied? | Specific Chart Evidence | |---|---|---| | Confirmed early symptomatic AD | Yes | Neurologist note dated [date], ICD-10 [code] | | Amyloid pathology confirmed | Yes | PET/CSF report dated [date], result summary | | Clinical staging within approved range | Yes | Assessment tool result from chart | | Prescriber is appropriate specialist | Yes | Neurologist NPI, board certification | | Any additional Aetna criteria | Address each | Cite specific record |

Close the letter by asking Aetna to identify, criterion by criterion, any gap that remains after reviewing the submitted documentation.